2 búsqueda de la palabra clave 'BK virus'

BK virus nephropathy in a heart transplant recipient / John Fredy Nieto Ríos ; Arbey Aristizabal Álzate ; Gustavo Adolfo Zuluaga Valencia    

Público ISBD Título : BK virus nephropathy in a heart transplant recipient Tipo de documento : documento electrónico Autores : John Fredy Nieto Ríos, ; Arbey Aristizabal Álzate, ; Gustavo Adolfo Zuluaga Valencia, Fecha de publicación : 2020 Títulos uniformes : Brazilian Journal of Nephrology Idioma : Inglés (eng) Palabras clave : Polyomavirus  BK virus  BK Virus Nephropathy  Organ Transplantation  Heart transplantation  Immunosuppression Resumen : BK virus nephropathy in kidney transplantation is widely recognized as an important cause of graft dysfunction and loss. In the case of transplants of organs other than kidney, BK virus nephropathy in native kidneys has been recognized as a cause of chronic kidney disease, which is related with immunosuppression; however, the diagnosis is usually late because the renal dysfunction is attributed to other causes, such as toxicity by anticalcineurinic drugs, interstitial nephritis due to medications, hemodynamic changes, diabetes, hypertension, etc. We report a case of BK virus nephropathy in a patient who underwent heart transplantation due to peripartum cardiomyopathy. The kidney biopsy reported active chronic tubulointerstitial nephritis associated with late stage polyomavirus nephritis and the blood viral load for BK virus was positive (logarithm 4.5). The immunosuppressive treatment was reduced, and after two years of follow-up, the patient had stable renal function with a serum creatinine of 2.5 mg/dL (GFR of 23.4 mL/min/1.73m2). We recommend that the BK virus be considered as a cause of renal dysfunction in heart transplant recipients, with the aim of detecting its replication in time to reduce immunosuppressive therapy before irreversible compromise of renal function may manifest. Mención de responsabilidad : John Fredy Nieto-Ríos, Diego Armando Benavides-Henao, Arbey Aristizabal-Alzate, Carol Morales-Contreras, Diana Carolina Chacón-Jaimes, Gustavo Zuluaga-Valencia, Lina María Serna-Higuita Referencia : J Bras Nefrol. Jul-Sep 2021;43(3):434-439. DOI (Digital Object Identifier) : 10.1590/2175-8239-jbn-2020-0049 PMID : 33527977 Derechos de uso : CC BY En línea : https://bjnephrology.org/en/article/bk-virus-nephropathy-in-a-heart-transplant-r [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5735 BK virus nephropathy in a heart transplant recipient [documento electrónico] / John Fredy Nieto Ríos, ; Arbey Aristizabal Álzate, ; Gustavo Adolfo Zuluaga Valencia,  . - 2020. Obra : Brazilian Journal of Nephrology Idioma : Inglés (eng) Palabras clave : Polyomavirus  BK virus  BK Virus Nephropathy  Organ Transplantation  Heart transplantation  Immunosuppression Resumen : BK virus nephropathy in kidney transplantation is widely recognized as an important cause of graft dysfunction and loss. In the case of transplants of organs other than kidney, BK virus nephropathy in native kidneys has been recognized as a cause of chronic kidney disease, which is related with immunosuppression; however, the diagnosis is usually late because the renal dysfunction is attributed to other causes, such as toxicity by anticalcineurinic drugs, interstitial nephritis due to medications, hemodynamic changes, diabetes, hypertension, etc. We report a case of BK virus nephropathy in a patient who underwent heart transplantation due to peripartum cardiomyopathy. The kidney biopsy reported active chronic tubulointerstitial nephritis associated with late stage polyomavirus nephritis and the blood viral load for BK virus was positive (logarithm 4.5). The immunosuppressive treatment was reduced, and after two years of follow-up, the patient had stable renal function with a serum creatinine of 2.5 mg/dL (GFR of 23.4 mL/min/1.73m2). We recommend that the BK virus be considered as a cause of renal dysfunction in heart transplant recipients, with the aim of detecting its replication in time to reduce immunosuppressive therapy before irreversible compromise of renal function may manifest. Mención de responsabilidad : John Fredy Nieto-Ríos, Diego Armando Benavides-Henao, Arbey Aristizabal-Alzate, Carol Morales-Contreras, Diana Carolina Chacón-Jaimes, Gustavo Zuluaga-Valencia, Lina María Serna-Higuita Referencia : J Bras Nefrol. Jul-Sep 2021;43(3):434-439. DOI (Digital Object Identifier) : 10.1590/2175-8239-jbn-2020-0049 PMID : 33527977 Derechos de uso : CC BY En línea : https://bjnephrology.org/en/article/bk-virus-nephropathy-in-a-heart-transplant-r [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5735

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001674	AC-2020-145	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2020-145 Adobe Acrobat PDF

Hemorrhagic cystitis after haploidentical transplantation with post-transplantation cyclophosphamide: protective effect of MESNA continuous infusion / Marcos Arango Barrientos  

Público ISBD Título : Hemorrhagic cystitis after haploidentical transplantation with post-transplantation cyclophosphamide: protective effect of MESNA continuous infusion Tipo de documento : documento electrónico Autores : Marcos Arango Barrientos, Fecha de publicación : 2020 Títulos uniformes : Biology of Blood and Marrow Transplantation Idioma : Inglés (eng) Palabras clave : BK virus  Cyclophosphamide  Cystitis  Haploidentical  MESNA  Transplantation Resumen : Hemorrhagic cystitis (HC) is an important complication after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide (PT-CY). Sodium 2-mercaptoethanesulfonate (MESNA) can prevent bladder injury when given with PT-CY. However, the best way to deliver MESNA is not known. This study assessed the incidence of HC after haplo-HSCT with PT-CY with 2 different methods of MESNA administration. The cumulative incidence of HC was lower in patients who received MESNA as a continuous infusion compared with those who received it as an intermittent bolus (5.6% versus 27.8%; P = .01). MESNA administration as an infusion was associated with a lower risk of developing HC (hazard ratio [HR], .19; 95% confidence interval [CI], .04 to .86; P = .02) on univariate analysis. This effect remained significant after adjustment in multivariate analysis (HR, .21; 95% CI, .04 to .88; P = .03). MESNA delivered as a continuous infusion is a simple and potentially useful way to prevent HC after PT-CY. Mención de responsabilidad : Marcos Arango, Doris Cardona Referencia : Biol Blood Marrow Transplant. 2020 Aug;26(8):1492-1496 DOI (Digital Object Identifier) : 10.1016/j.bbmt.2020.04.028 PMID : 32417488 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1083879120302834 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5119 Hemorrhagic cystitis after haploidentical transplantation with post-transplantation cyclophosphamide: protective effect of MESNA continuous infusion [documento electrónico] / Marcos Arango Barrientos,  . - 2020. Obra : Biology of Blood and Marrow Transplantation Idioma : Inglés (eng) Palabras clave : BK virus  Cyclophosphamide  Cystitis  Haploidentical  MESNA  Transplantation Resumen : Hemorrhagic cystitis (HC) is an important complication after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide (PT-CY). Sodium 2-mercaptoethanesulfonate (MESNA) can prevent bladder injury when given with PT-CY. However, the best way to deliver MESNA is not known. This study assessed the incidence of HC after haplo-HSCT with PT-CY with 2 different methods of MESNA administration. The cumulative incidence of HC was lower in patients who received MESNA as a continuous infusion compared with those who received it as an intermittent bolus (5.6% versus 27.8%; P = .01). MESNA administration as an infusion was associated with a lower risk of developing HC (hazard ratio [HR], .19; 95% confidence interval [CI], .04 to .86; P = .02) on univariate analysis. This effect remained significant after adjustment in multivariate analysis (HR, .21; 95% CI, .04 to .88; P = .03). MESNA delivered as a continuous infusion is a simple and potentially useful way to prevent HC after PT-CY. Mención de responsabilidad : Marcos Arango, Doris Cardona Referencia : Biol Blood Marrow Transplant. 2020 Aug;26(8):1492-1496 DOI (Digital Object Identifier) : 10.1016/j.bbmt.2020.04.028 PMID : 32417488 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1083879120302834 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5119

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001376	AC-2020-054	Archivo digital	Producción Científica	Artículos científicos	Disponible